Market revenue in 2023 | USD 1,379.8 million |
Market revenue in 2030 | USD 2,331.8 million |
Growth rate | 7.8% (CAGR from 2023 to 2030) |
Largest segment | Product |
Fastest growing segment | Service |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Product, Service |
Key market players worldwide | Agilent Technologies Inc, Illumina Inc, Qiagen NV, Thermo Fisher Scientific Inc, Roche, ARUP Laboratories, Abbott Laboratories, Myriad Genetics Inc, BioMerieux SA |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to oncology companion diagnostic market will help companies and investors design strategic landscapes.
Product was the largest segment with a revenue share of 66.51% in 2023. Horizon Databook has segmented the Europe oncology companion diagnostic market based on product, service covering the revenue growth of each sub-segment from 2018 to 2030.
Europe accounts for a considerable revenue share of the oncology companion diagnostic market due to the presence of developed economies, such as Germany, Spain, the UK, France, and Italy. These countries have advanced infrastructure, which is anticipated to significantly boost clinical research prospects in the region.
Moreover, the growing biotechnology industry and rising investments in genomic sequencing in countries such as the UK & Germany are other major factors expected to improve market growth over the coming decade. The rising prevalence and mortality rates of cancer are key drivers in the healthcare market, leading to increased demand for advanced diagnostic technologies, including CDx tests that enhance early detection and treatment outcomes.
With an aging population, the burden of cancer in the European Union (EU) is escalating, shown by 2.7 million new cases and an estimated 1.3 million cancer-related deaths in 2022. According to the European Cancer Information System's 2022 statistics, colorectal, breast, cervical, lung, prostate, and gastric cancers account for 54.2% of all new cancer cases and 50.2% of cancer deaths in the EU.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe oncology companion diagnostic market , including forecasts for subscribers. This continent databook contains high-level insights into Europe oncology companion diagnostic market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account